protein engineering | Sutro Biopharma, Inc.

American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 – STRO-002 Abstract

American Association for Cancer Research (AACR) Virtual Annual Meeting 2020 – STRO-002 Abstract STRO-002-GM1, a first in human, phase 1 Study of STRO-002, an anti-Folate Receptor alpha (FRα) Antibody Drug Conjugate (ADC), in Patients with Advanced...

Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate

Events, News, Presentations, Press Releases

Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate -Company to present updated STRO-002 data at AACR Virtual Annual Meeting – SOUTH SAN FRANCISCO, Calif., April 20, 2020 – Sutro...

Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020

Events, News, Presentations, Press Releases

Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020 – Company to host a conference call following the presentation – SOUTH SAN FRANCISCO, Calif., April. 13, 2020 –...

Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference

Events, News, Press Releases

Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 8, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...

Open Letter From Our CEO

News

Open Letter From Our CEO Hi All, For several years I have been troubled by the levels of public antipathy (if not outright scorn) for our industry. Routinely biotech (not just pharma) is held in low esteem by the American public – effectively on a par with the...

« Older Entries

Next Entries »